Merrill Lynch is rating Elan as a buy for investors. The Irish-based pharmaceutical company has fallen out of favour with the market recently. It is expected to launch three new drugs next year, while new accounting practices are expected to raise the quality of the group's earnings next year. Merrill Lynch is forecasting the stock will trade up to $45 (€44).
IN THIS SECTION
I’m not across all the conspiracy lore around Sean ‘Diddy’ Combs, but the gist is that he’s a CIA asset
No election is a foregone conclusion. This will be a fierce and frantic week
Opposition to abortion is seen as a position of the right, but it’s not that simple
Balmoral shows ‘small’ investors the door
An Irish businessman in Singapore: ‘You’ll get a year in jail if you are in a drunken brawl, so people don’t step out of line’
Business Today
Get the latest business news and commentary from our expert business team in your inbox every weekday morning